- The patient must have an ECOG performance status of 0 or 1
- Patient must have clinically T1-3, N1 breast cancer at the time of diagnosis (before neoadjuvant therapy)
- Patient must have had pathologic confirmation of axillary nodal involvement at presentation based on either a positive FNA or positive core needle biopsy
- Patient must have completed a minimum of 8 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen
Please contact Legacy Oncology Research for additional study inclusion/exclusion information.